The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The company, which is collaborating with Myeloma Crowd, will use the newly-licensed minicircle DNA technology to develop therapies for multiple myeloma.
The partners aim to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve disease diagnosis, prognosis, and treatment.
The researchers' analysis of single circulating multiple myeloma tumor cells found that the results were similar to analysis of bone marrow biopsy samples.
The test is designed to replace gel electrophoresis assays currently used for measuring M-proteins, biomarkers for plasma cell diseases such as multiple myeloma.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
